RxDoctor Payments Data

Haider Nazeer, MD

Cardiovascular Disease · Plano, TXNPI 1457779308

Payments from drug & device makers

$33,062in general payments, 2019–2025

Across 181 payments — averaging $182.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Abbott$13K
  • Biotronik Inc.$2K
  • Abiomed$959
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$826
  • AstraZeneca$631
  • plus $3K from 25 others

What the payments were for

  • Grants$21,25064%
  • Travel & lodging$4,16313%
  • Food & beverage$7,50023%
  • Education$1500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,062 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$140,289
Medicare patients
378
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis71$2,117,360
JardianceEmpagliflozin205$236,388
EntrestoSacubitril/Valsartan135$164,598
FarxigaDapagliflozin Propanediol63$72,339
EliquisApixaban37$44,921
XareltoRivaroxaban16$17,783
Metoprolol Succinate173$3,061
Eplerenone20$2,168
Spironolactone217$1,572
Torsemide99$1,559
Midodrine Hcl13$990
Furosemide81$547
Ezetimibe18$396
Atorvastatin Calcium49$383
Rosuvastatin Calcium19$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$246$2,162,281108 claims
Boehringer IngelheimJardiance$242$236,388205 claims
NovartisEntresto$248$164,598135 claims
AstraZenecaFarxiga$631$72,33963 claims
Johnson & JohnsonXarelto$124$17,78316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →